Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pompe disease
Pharma
BioMarin lays off staffers at recently-acquired Amicus
Shortly after locking down its $4.8 billion deal for rare disease peer Amicus, BioMarin is pruning the acquired company's ranks.
Fraiser Kansteiner
May 12, 2026 5:12pm
BioMarin makes its largest transaction, paying $4.8B for Amicus
Dec 19, 2025 11:28am
Eisai, Takeda, BIOSECURE Act—Fierce Pharma Asia
May 17, 2024 8:30am
Amicus scores $430M financing deal with asset manager Blackstone
Oct 2, 2023 4:16pm
FDA OKs Amicus Pompe combo, setting up market battle with Sanofi
Sep 28, 2023 3:15pm
Amicus' Pompe approval portends a showdown with Sanofi
Mar 28, 2023 10:25am
